At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tofacitinib for the Treatment of Inflammatory Eye Disease
In Brief
A Phase 2 clinical trial evaluating tofacitinib for Uveitis and Scleritis. Targeting 5 participants across 1 site.
Detailed Summary
Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.
Study Details
Timeline
Interventions
tofacitinib extended release, 11mg, daily, oral